Inhaled corticosteroids for the treatment of COVID‐19.

Keywords: basic mechanisms; pneumology; prevention; quality-of-life; virus EN basic mechanisms pneumology prevention quality-of-life virus 986 988 3 10/09/23 20231001 NES 231001 Key messages ICS probably reduce risk of hospital admission and death in patients with mild COVID-19. ICS may increase symptom resolution at 14 days in patients with mild COVID-19. Only 10% of participants had received >1 COVID-19 vaccination at the time of involvement, whereas mass vaccination programmes have now administered 13.2 billion doses globally, associated with reduced COVID-19 death rate.[7] Additionally, several COVID-19 variants with varying symptom and virulence profiles have since developed. [Extracted from the article]